The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Incidence and clinical characteristics of gastroenteropancreatic neuroendocrine tumor in Korea: a single-center experience

  • Lim, Chul-Hyun (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Lee, In Seok (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Jun, Byoung Yeon (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Kim, Jin Su (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Cho, Yu Kyung (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Park, Jae Myung (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Roh, Sang Young (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Lee, Myung Ah (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Kim, Sang Woo (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Choi, Myung-Gyu (Department of Internal Medicine, College of Medicine, The Catholic University of Korea)
  • Received : 2015.07.21
  • Accepted : 2015.12.03
  • Published : 2017.05.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Neuroendocrine tumors (NETs) may originate from heterogeneous neuroendocrine cells. The incidence is increasing worldwide, and World Health Organization (WHO) updated its classification in 2010. We investigated clinical characteristics of gastroenteropancreatic NETs in a single center. Methods: Clinicopathologic characteristics of patients with pathologically confirmed gastroenteropancreatic NET in Seoul St. Mary Hospital from March 2009 to August 2011 were retrospectively analyzed. The grade and stage were determined according to WHO 2010 classification and TNM Staging System for Neuroendocrine Tumors (7th ed., 2010) of American Joint Committee on Cancer. Results: One hundred and twenty-five patients (median age, 50; male, 61.3%) were analyzed. Among 100,000 patients who visited the hospital, incidence was 24.1. Only two patients (1.6%) had a functional NET. The rectum (n = 99, 79.8%) was most common primary site and found in early stage. The prevalence by stages was 84.7% stage I, 8.9% stage IV, 4.8% stage II, and 1.6% stage III. The pathology grading was 74.5% grade 1, 12.7% grade 2, and 12.7% grade 3. Tumor stage correlated positively with pathologic grade (Spearman's rank correlation coefficient, 0.644). Conclusions: Wide range of clinicopathological features of Korean gastroenteropancreatic NETs were demonstrated using WHO 2010 classification. Rectal NET was most frequent and found in early stage.

Keywords

References

  1. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072. https://doi.org/10.1200/JCO.2007.15.4377
  2. Ferrone CR, Tang LH, Tomlinson J, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 2007;25:5609-5615. https://doi.org/10.1200/JCO.2007.12.9809
  3. Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008;113:2655-2664. https://doi.org/10.1002/cncr.23883
  4. Ito T, Sasano H, Tanaka M, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010;45:234-243. https://doi.org/10.1007/s00535-009-0194-8
  5. Oberg K. Expression of growth factors and their receptors in neuroendocrine gut and pancreatic tumors, and prognostic factors for survival. Ann N Y Acad Sci 1994;733:46-55. https://doi.org/10.1111/j.1749-6632.1994.tb17255.x
  6. Moyana TN. Gastrointestinal endocrine cells and carcinoids: histogenetic and pathogenetic considerations. Pathol Annu 1995;30(Pt 1):227-246.
  7. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-959. https://doi.org/10.1002/cncr.11105
  8. Mani S, Modlin IM, Ballantyne G, Ahlman H, West B. Carcinoids of the rectum. J Am Coll Surg 1994;179:231-248.
  9. Godwin JD 2nd. Carcinoid tumors: an analysis of 2,837 cases. Cancer 1975;36:560-569. https://doi.org/10.1002/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4
  10. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79:813-829.
  11. Bosman FT; World Health Organization; International Agency for Research on Cancer. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: International Agency for Research on Cancer, 2010.
  12. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451:757-762. https://doi.org/10.1007/s00428-007-0452-1
  13. Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005;54 Suppl 4:iv1-iv16.
  14. Plockinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours: a consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004;80:394-424. https://doi.org/10.1159/000085237
  15. Oberg K, Jelic S; ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and followup. Ann Oncol 2009;20 Suppl 4:150-153.
  16. Oberg K, Astrup L, Eriksson B, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms): part II-specific NE tumour types. Acta Oncol 2004;43:626-636. https://doi.org/10.1080/02841860410018584
  17. Oberg K, Astrup L, Eriksson B, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms): part I-general overview. Acta Oncol 2004;43:617-625. https://doi.org/10.1080/02841860410018575
  18. Lim T, Lee J, Kim JJ, et al. Gastroenteropancreatic neuroendocrine tumors: incidence and treatment outcome in a single institution in Korea. Asia Pac J Clin Oncol 2011;7:293-299. https://doi.org/10.1111/j.1743-7563.2011.01423.x
  19. Gastrointestinal Pathology Study Group of Korean Society of Pathologists, Cho MY, Kim JM, et al. Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000-2009: multicenter study. Cancer Res Treat 2012;44:157-165. https://doi.org/10.4143/crt.2012.44.3.157
  20. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401. https://doi.org/10.1007/s00428-006-0250-1
  21. Scarpa A, Mantovani W, Capelli P, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010;23:824-833. https://doi.org/10.1038/modpathol.2010.58
  22. Fischer L, Kleeff J, Esposito I, et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg 2008;95:627-635. https://doi.org/10.1002/bjs.6051
  23. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008;14:7798-7803. https://doi.org/10.1158/1078-0432.CCR-08-0734
  24. Lee H, Choi J, An JS, et al. The clinicopathological characteristics of gastrointestinal neuroendocrine tumors: an analysis of 65 cases. Korean J Pathol 2007;41:149-157.
  25. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12:1083-1092. https://doi.org/10.1677/erc.1.01017
  26. Pape UF, Berndt U, Muller-Nordhorn J, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008;15:1083-1097. https://doi.org/10.1677/ERC-08-0017
  27. Rothenstein J, Cleary SP, Pond GR, et al. Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital. Am J Clin Oncol 2008;31:64-70. https://doi.org/10.1097/COC.0b013e31807a2f49
  28. Grama D, Eriksson B, Martensson H, et al. Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg 1992;16:632-639. https://doi.org/10.1007/BF02067341
  29. Shebani KO, Souba WW, Finkelstein DM, et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 1999;229:815-821. https://doi.org/10.1097/00000658-199906000-00008
  30. Sutton R, Doran HE, Williams EM, et al. Surgery for midgut carcinoid. Endocr Relat Cancer 2003;10:469-481. https://doi.org/10.1677/erc.0.0100469
  31. Colonoscopy Study Group of Korean Society of Coloproctology. Clinical characteristics of colorectal carcinoid tumors. J Korean Soc Coloproctol 2011;27:17-20. https://doi.org/10.3393/jksc.2011.27.1.17

Cited by

  1. Proper Treatment Option for Small Rectal Neuroendocrine Tumors Using Precut Endoscopic Mucosal Resection vol.50, pp.6, 2017, https://doi.org/10.5946/ce.2017.182
  2. Factors Affecting Survival in Neuroendocrine Tumors: A 15-Year Single Center Experience vol.19, pp.12, 2017, https://doi.org/10.31557/apjcp.2018.19.12.3597
  3. Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study vol.12, pp.None, 2019, https://doi.org/10.2147/ott.s182259
  4. Clinical analysis of 547 patients with neuroendocrine tumors in a Chinese population: A single‐center study vol.8, pp.8, 2017, https://doi.org/10.1002/cam4.2259
  5. Clinicopathological Study of 100 Cases of Neuroendocrine Neoplasms of the Gastroenteropancreatic System: A Tertiary Cancer Center Experience vol.41, pp.3, 2020, https://doi.org/10.4103/ijmpo.ijmpo_217_18